Immunoglobulin-resistant Kawasaki disease
Open Access
- 5 September 2023
- journal article
- research article
- Published by Instituto Mexicano del Seguro Social in Boletín Médico del Hospital Infantil de México
- Vol. 80 (4) , 260-264
Abstract
Background: Kawasaki disease is a systemic vasculitis that affects small and medium-sized vessels, primarily the coronary arteries. First-line treatment includes intravenous immunoglobulin (IVIG) and acetylsalicylic acid; however, 20% do not respond adequately despite treatment. We describe a case treated with etanercept after initial IVIG failure, showing a good response. Case report: A 5-year-old female was diagnosed with classic Kawasaki disease. Echocardiography and angiotomography revealed giant and fusiform aneurysms in the coronary arteries. A first dose of IVIG therapy was administered without improvement; after the second dose, the fever persisted, so etanercept was administered, and the fever subsided. There were no new lesions in medium-caliber vessels and the previously identified coronary lesions did not progress. Conclusions: The use of etanercept in Kawasaki disease has demonstrated a clinically favorable response. Controlled clinical trials of this drug are needed to establish it as a formal therapy in cases of initial IVIG failure.Keywords
This publication has 13 references indexed in Scilit:
- Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trialCardiology in the Young, 2022
- 2021 Update on the Clinical Management and Diagnosis of Kawasaki DiseaseCurrent Infectious Disease Reports, 2021
- Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic reviewPediatric Rheumatology, 2019
- TNF-α blockers for the treatment of Kawasaki disease in childrenCochrane Database of Systematic Reviews, 2019
- Infliximab Therapy and the Central Nervous Demyelination in Patients with Kawasaki DiseaseThe Pediatric Infectious Disease Journal, 2019
- Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki diseaseBMC Pediatrics, 2019
- Infliximab for the treatment of Kawasaki diseasePediatrics International, 2018
- Aneurismas coronarios gigantes en lactantes con enfermedad de KawasakiAnales de Pediatría, 2017
- Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart AssociationCirculation, 2017
- Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki DiseaseThe Journal of Pediatrics, 2010